Indolent B-cell non-Hodgkin lymphoma

This study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…

This study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This early-stage study is testing a combination of three drugs (alisertib, bortezomib, and rituximab) in about 24 people with mantle cell or low-grade non-Hodgkin lymphoma that has returned or stopped responding to prior treatments. The main goal is to find the safest dose of the…

This trial tests a type of engineered immune cell therapy called 19(T2)28z1xx CAR T cells in adults with B-cell cancers that have returned or not responded to treatment. The main goal is to find the highest dose that causes few or mild side effects. Researchers will also check wh…

This early-phase trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The ther…

This early-phase trial tests a combination of two drugs—copanlisib and nivolumab—in people with Richter's transformation or certain non-Hodgkin lymphomas that have become aggressive. The study aims to find the best dose and check for side effects. A total of 27 participants will …

This phase II trial is testing two drugs, obinutuzumab and ibrutinib, as the first treatment for people with indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. The goal is to see how many patients respond to the combination. The study involves 30 participants and is no…

This early study tests a new drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug is a pill that targets a protein (BTK) involved in cancer growth. The main goals are to find a safe dose and s…

This phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus st…

This study tests whether a very low dose of radiation (4 Gy) can control slow-growing B-cell lymphoma in the eye socket. About 50 adults with stage I-IV indolent lymphoma or mantle cell lymphoma will receive this targeted treatment. The goal is to shrink or stop the cancer while …

This early-phase trial tests a new approach to treating certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatment. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells (SYNCAR-001), alon…

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions o…

This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…

This early-phase study tests the safety of specially engineered immune cells (armored CAR T cells) in people with certain blood cancers that have not responded to standard treatments. The cells are made from the patient's own blood and designed to better target and attack cancer …

This phase 2 trial is testing an experimental cell therapy called TAK-007 in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. Participants first receive chemotherapy to lower certain white blood cells, then get one or three injections o…

This phase 2 trial is testing a personalized cell therapy called axi-cel for people with aggressive B-cell lymphoma that has come back or not responded to treatment, and who cannot undergo a stem cell transplant. The therapy uses the patient's own immune cells, which are modified…

This phase 2 trial is testing a combination of two immunotherapy drugs, glofitamab and obinutuzumab, as the first treatment for people with follicular lymphoma or marginal zone lymphoma. The study includes 47 participants who have not had prior therapy for their lymphoma. The goa…

This study tests an experimental drug called valemetostat tosylate in people with B-cell lymphoma whose cancer has returned or not responded to prior treatments. About 141 participants will receive the drug to see if it can shrink tumors. The goal is to find a new option for hard…

This phase 2 trial is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can improve outcomes for people with aggressive B-cell non-Hodgkin lymphoma. The study enrolls 30 patients with various subtypes of the disease. The main g…

This study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. About 50 adults will take part to find the best dose and see if the combination is safe and works better than standard …

This phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…

This study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced or returning ly…

This early-phase trial is testing whether giving low-dose radiation before CAR T-cell therapy is feasible and safe for people with B-cell lymphoma that has come back or not responded to treatment. About 33 participants will receive two small doses of radiation, then standard CAR …

This was a phase I trial testing a new drug called CB-5339 in people with advanced solid tumors or lymphomas. The drug was designed to block certain enzymes that cancer cells need to grow. However, the study was withdrawn before enrolling any participants, so no results or safety…

This early-phase trial is testing the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in patients with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The study enrolled only 4 participants to …

This phase 2 study tests an oral drug called ME-401 in 61 Japanese adults with a slow-growing form of non-Hodgkin's lymphoma that has returned or not responded to at least two prior treatments. The drug is taken daily for the first two months, then on a weekly schedule. Researche…